Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis

Table 1

Clinicopathological data per group.

Diagnosis	Sex (M/F)	Age (yrs)	PMD (hrs: min)	Brain weight (gr.)	Age of onset (yrs)	Disease duration (yrs)	GDS	PD Braak stage
Control	7/3	82	06:07	1350	—	—	n.d.	0 (𝑛=6)
PD	7/2	79	05:35	1289	64	15	n.d.	5.0 (𝑛=5)
PDD	7/4	76	05:50	1276	69	10	5 (𝑛=7)	6.0 (𝑛=8)
DLB	7/3	75	04:20	1211	66	7	7 (𝑛=10)	5.0 (𝑛=2)

Median values are given; Control: nondemented control; PD: Parkinson’s disease; PDD: PD with dementia; DLB: dementia with Lewy bodies; M: males; F: females; PMD: postmortem delay; GDS: global deterioration scale [16]; n.d.: not determined. There is no significant difference between the age (𝑃=0.301), the brain weight (𝑃=0.284), and the postmortem delay (PMD; 𝑃=0.229) of the groups. The mean GDS scores of the DLB group significantly higher than of the PDD group (𝑃=0.004). All other donor parameters, such as amyloid pathology and ApoE genotype (see also Tables 1 and 2), were not significantly different between the groups.